Antonia Strippoli

INFINITY: A multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC).

Filippo Pietrantonio, Alessandra Raimondi, Sara Lonardi et al. · Journal of Clinical Oncology · 2023 · 93 citations

Medicine, Oncology, Pharmacotherapy +15

Is There a Role for IGF1R and c-MET Pathways in Resistance to Cetuximab in Metastatic Colorectal Cancer?

Alessandro Inno, Mariantonietta Di Salvatore, Tonia Cenci et al. · Clinical Colorectal Cancer · 2011 · 84 citations

Medicine, Oncology, Pharmacology +14

Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer

Ina Valeria Zurlo, Mattia Schino, Antonia Strippoli et al. · Cancer Immunology Immunotherapy · 2021 · 79 citations · Full text

Medicine, Oncology, Surgery +17

c-MYC Expression Is a Possible Keystone in the Colorectal Cancer Resistance to EGFR Inhibitors

Antonia Strippoli, Alessandra Cocomazzi, Michele Basso et al. · Cancers · 2020 · 78 citations · Full text

Medicine, Molecular Biology, Oncology +17

Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO

A. Raimondi, Sara Lonardi, Sabina Murgioni et al. · Annals of Oncology · 2024 · 72 citations · Full text

Medicine, Oncology, Pathology +17